GHRH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-28. Numbers and descriptions here follow the published literature rather than marketing material.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual descriptor; not a measure of purity |
| Solubility class | Freely soluble in water | Aqueous dissolution may require gentle mixing |
| Typical storage (powder) | −20 °C or below, desiccated | Protect from light and ambient moisture |
| Typical storage (solution) | 2–8 °C, short term | Freeze aliquots where longer holding is needed |
| Purity assessment | Reversed-phase HPLC, area percent | Values depend on column, gradient, and detection wavelength |
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
== Medical uses == Lurbinectedin is indicated for the treatment of adults with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy. In October 2025, the indication for lurbinectedin was expanded to include using lurbinectedin in combination with atezolizumab or in combination with atezolizumab/hyaluronidase for the maintenance treatment of adults with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase, carboplatin, and etoposide.
Generally, fatty acids (FAs) can be defined as organic compounds containing a carboxyl group (–COOH) at one end of an aliphatic hydrocarbon chain (also called the "front" end of the molecule), and a methyl group (–CH3) at the opposite end (also called the "methyl" end of the molecule). Fatty acid chains commonly contain anywhere from 4 to 24 carbon atoms, but they are known to reach up to 44 carbon atoms in length. Fatty acid chains typically contain an even number of carbon atoms (i.e., 10, 12, 16) and a linear structure about the acyl chain, though both odd-numbered and branched fatty acids also exist. Fatty acids can be categorized according to the degree of saturation (number of double bonds) present about the aliphatic hydrocarbon chain. Saturated fatty acids (SFAs) have no double bonds. Monounsaturated fatty acids (MUFAs) have one double bond, while polyunsaturated fatty acids (PUFAs) have two or more double bonds present about the acyl chain. Two discrete nomenclature systems are used for describing fatty acids: omega (ω–x) nomenclature and delta (Δ) nomenclature, in addition to simple common names. Within the fields of medicine and nutrition, both common names and omega nomenclature are frequently used to discuss fatty acids. In biochemistry and lipids research, fatty acid common names, omega nomenclature, and delta nomenclature are all widely used, but delta nomenclature is more typically seen in discussions on specific fatty acids. Additionally, common fatty acid names are often denoted alongside a shorthand notation (i.e., palmitic acid (C16:0)).
== Toxicity == A subacute rodent NOAEL of 43 μg/kg body weight as well as genotoxicity studies were primarily the cause for setting limits for patulin exposure, although a range of other types of toxicity also exist. While not a particularly potent toxin, patulin is genotoxic. Some theorize that it may be a carcinogen, although animal studies have remained inconclusive. Patulin has shown antimicrobial properties against some microorganisms. Several countries have instituted patulin restrictions in apple products. The World Health Organization recommends a maximum concentration of 50 μg/L in apple juice. In the European Union, the limit is also set at 50 micrograms per kilogram (μg/kg) in apple juice and cider, at 25 μg/kg in solid apple products, and at 10 μg/kg in products for infants and young children. These limits came into force on 1 November 2003.
Sources: en.wikipedia.org
The EFSA reviewed the same safety question and set its UL at 25 mg/day, which is much lower than the U.S. value. For U.S. food and dietary supplement labeling purposes the amount in a serving is expressed as a percent of Daily Value (%DV). For zinc labeling purposes 100% of the Daily Value was 15 mg, but on May 27, 2016, it was revised to 11 mg. A table of the old and new adult daily values is provided at Reference Daily Intake.
=== Biotransformation === Caffeate O-methyltransferase is an enzyme responsible for the transformation of caffeic acid into ferulic acid. Caffeic acid and related o-diphenols are rapidly oxidized by o-diphenol oxidases in tissue extracts.
== What does it deliver? == DNA extraction is frequently a preliminary step in many diagnostic procedures used to identify environmental viruses and bacteria and diagnose illnesses and hereditary diseases. These methods consist of, but are not limited to: Fluorescence In Situ Hybridization (FISH) technique was developed in the 1980s. The basic idea is to use a nucleic acid probe to hybridize nuclear DNA from either interphase cells or metaphase chromosomes attached to a microscopic slide. It is a molecular method used, among other things, to recognize and count particular bacterial groupings. To recognize, define, and quantify the geographical and temporal patterns in marine bacterioplankton communities, researchers employ a technique called terminal restriction fragment length polymorphism (T-RFLP). Sequencing: Whole or partial genomes and other chromosomal components, ended for comparison with previously published sequences.
Glucokinase activity can be amplified or reduced in minutes by actions of the glucokinase regulatory protein (GKRP). The actions of this protein are influenced by small molecules such as glucose and fructose. The amount of glucokinase can be increased by synthesis of new protein. Insulin is the principal signal for increased transcription, operating mainly by way of a transcription factor called sterol regulatory element binding protein-1c (SREBP1c) in the liver. This occurs within an hour after a rise in insulin levels, as after a carbohydrate meal.
Sources: en.wikipedia.org
This system is particularly important in the brain, where zinc signaling is prominent both between and within nerve cells. It also seems to be important for the regulation of the tumor suppressor protein p53.
Although Southern Rhodesia never gained full Dominion status within the Commonwealth of Nations, Southern Rhodesians ruled themselves from the attainment of 'Responsible Government' in 1923. Its electoral register had property and education qualifications. Over the years various electoral arrangements made at a national and municipal level upheld these standards. For example, the franchise for the first Southern Rhodesian Legislative Council election in 1899 contained the following requirement:
=== Inequalities === People living with AD and other forms of dementia and their unpaid carers might face inequalities in access to and the quality of care and support services. These inequalities can depend on various factors, including socio-economic background, housing situation, education level, gender, and race. People might have differences in how easily they can access AD services based on where they live. On a global level, people in low-and middle-income countries have fewer available facilities and services, and have greater difficulties accessing these than people living in high-income countries. As a result of AD and other forms of dementia being less recognised and treated in the healthcare systems of these countries, the level of awareness of AD as something caused by disease is relatively lower. At the same time, the local socio-cultural understandings of aging, senility, and eldercare may have larger effects on care provision and the reception of medical services. On a national level, people with AD might have unequal access to care based on where they live. This can manifest on a regional level, with people in rural areas facing more difficulties than those in urban areas. Inequalities can also affect smaller local units as well, for example people living in the same city might receive different or less frequent care based on their postcodes or the street they live in. Inequalities also affect people with AD from ethnic minority groups.
Giddings also envisioned the capabilities of Supercritical fluid chromatography, by developing the theory and ground work of dense gas chromatographic system. Eventually Prof Giddings invented the one-phase separation technique called "field-flow fractionation" (FFF). He developed the concept of a chromatographic-like system in which retention is established and controlled by an external field rather than by the stationary phase. The FFF system extends the range of chromatography upward to include macromolecules and particles of almost every type and size, from 0.001 to 10 μm and beyond. He was nominated for a Nobel Prize in 1984 and 1994. Giddings received numerous honors for his work including American Chemical Society Awards in Chromatography and Electrophoresis, in Analytical Chemistry, and in Separation Science and Technology. He also received the Tswett Medal in Chromatography, and the Nichols Medical from the New York Section of the ACS. On May 27, 1987, Giddings received an honorary doctorate from the faculty of pharmacy at Uppsala University, Sweden He died of cancer in 1996.
The term bioorthogonal chemistry refers to any chemical reaction that can occur inside of living systems without interfering with native biochemical processes. The term was coined by Carolyn R. Bertozzi in 2003. Since its introduction, the concept of the bioorthogonal reaction has enabled the study of biomolecules such as glycans, proteins, and lipids in real time in living systems without cellular toxicity. A number of chemical ligation strategies have been developed that fulfill the requirements of bioorthogonality, including the 1,3-dipolar cycloaddition between azides and cyclooctynes (also termed copper-free click chemistry), between nitrones and cyclooctynes, oxime/hydrazone formation from aldehydes and ketones, the tetrazine ligation, the isocyanide-based click reaction, and most recently, the quadricyclane ligation.
Sources: en.wikipedia.org
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.
There is no single agreed limit, and laboratory practice varies widely. Refrigeration slows degradation, and freezing aliquots is often described for longer holding. Any visible cloudiness or precipitate indicates the solution should be discarded.
Mass spectrometry provides the most direct confirmation through molecular mass. Reversed-phase chromatography supports purity assessment, and peptide mapping or amino acid analysis can corroborate sequence. No single method establishes both purity and identity on its own.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.